Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 172 articles:
HTML format
Text format



Single Articles


    March 2017
  1. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003831.
    PubMed     Text format     Abstract available


    February 2017
  2. SIDHOM Y, Maillart E, Tezenas du Montcel S, Kacem I, et al
    Fast multiple sclerosis progression in North Africans: Both genetics and environment matter.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003762.
    PubMed     Text format     Abstract available


  3. MOWRY EM, McArthur JC
    PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003749.
    PubMed     Text format    


  4. EIJLERS AJ, Meijer KA, Wassenaar TM, Steenwijk MD, et al
    Increased default-mode network centrality in cognitively impaired multiple sclerosis patients.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003689.
    PubMed     Text format     Abstract available


  5. BARTON J, Hardy TA, Riminton S, Reddel SW, et al
    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003694.
    PubMed     Text format    


  6. BODINI B, Calabresi PA
    From neurofilament research to multiple sclerosis clinical practice: Where do we stand?
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003676.
    PubMed     Text format    


  7. FILLI L, Zorner B, Kapitza S, Reuter K, et al
    Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003656.
    PubMed     Text format     Abstract available


  8. BENNETT SE
    Fampridine: Long-term benefits in walking in multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003677.
    PubMed     Text format    


    January 2017
  9. BARGIELA D, Bianchi MT, Westover MB, Chibnik LB, et al
    Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
    Neurology. 2017 Jan 13. pii: 10.1212/WNL.0000000000003612.
    PubMed     Text format     Abstract available


  10. BUTTON J, Al-Louzi O, Lang A, Bhargava P, et al
    Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
    Neurology. 2017 Jan 11. pii: 10.1212/WNL.0000000000003582.
    PubMed     Text format     Abstract available


    November 2016
  11. NIELSEN NM, Munger KL, Koch-Henriksen N, Hougaard DM, et al
    Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003454.
    PubMed     Text format     Abstract available


  12. TENSER RB, Truini A, Cruccu G
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016;87:2385-2386.
    PubMed     Text format    



  13. Pediatric multiple sclerosis: The 2015 Sydney Carter Award Lecture.
    Neurology. 2016;87:2284.
    PubMed     Text format    


  14. BEADNALL HN, Gill AJ, Riminton S, Barnett MH, et al
    Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003434.
    PubMed     Text format    



  15. Pediatric multiple sclerosis: Conventional first-line treatment and general management.
    Neurology. 2016;87:2068.
    PubMed     Text format    


  16. ESHAGHI A, Wottschel V, Cortese R, Calabrese M, et al
    Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2016 Nov 2. pii: 10.1212/WNL.0000000000003395.
    PubMed     Text format     Abstract available


    October 2016
  17. BOURDETTE D
    Rituximab for treating multiple sclerosis: Off-label but on target.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003345.
    PubMed     Text format    


  18. SALZER J, Svenningsson R, Alping P, Novakova L, et al
    Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003331.
    PubMed     Text format     Abstract available


    September 2016
  19. DORANS KS, Massa J, Chitnis T, Ascherio A, et al
    Physical activity and the incidence of multiple sclerosis.
    Neurology. 2016 Sep 28. pii: 10.1212/WNL.0000000000003260.
    PubMed     Text format     Abstract available


  20. KANTOR D, Sotirchos ES, Calabresi PA
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:1424.
    PubMed     Text format    


  21. COTTER J, Firth J, Enzinger C, Kontopantelis E, et al
    Social cognition in multiple sclerosis: A systematic review and meta-analysis.
    Neurology. 2016 Sep 21. pii: 10.1212/WNL.0000000000003236.
    PubMed     Text format     Abstract available


  22. KELLY DM, Kelleher EM, O'Shea A, Sweeney B, et al
    Teaching Video NeuroImages: Primary writing tremor: Lessons from a patient with multiple sclerosis.
    Neurology. 2016;87:e131.
    PubMed     Text format    


  23. BOVE R, White CC, Fitzgerald KC, Chitnis T, et al
    Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.
    Neurology. 2016 Sep 7. pii: 10.1212/WNL.0000000000003176.
    PubMed     Text format     Abstract available


  24. VOSKUHL R, Patti F
    Hormone replacement in menopausal women with multiple sclerosis: Looking back, thinking forward.
    Neurology. 2016 Sep 7. pii: 10.1212/WNL.0000000000003189.
    PubMed     Text format    


    August 2016
  25. SOLOMON AJ, Bourdette DN, Cross AH, Applebee A, et al
    The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2016 Aug 31. pii: 10.1212/WNL.0000000000003152.
    PubMed     Text format     Abstract available


  26. GHEZZI A, Amato MP, Makhani N, Shreiner T, et al
    Pediatric multiple sclerosis: Conventional first-line treatment and general management.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  27. BANWELL B, Arnold DL, Tillema JM, Rocca MA, et al
    MRI in the evaluation of pediatric multiple sclerosis.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  28. AMATO MP, Krupp LB, Charvet LE, Penner I, et al
    Pediatric multiple sclerosis: Cognition and mood.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  29. WALDMAN A, Ness J, Pohl D, Simone IL, et al
    Pediatric multiple sclerosis: Clinical features and outcome.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  30. HINTZEN RQ, Dale RC, Neuteboom RF, Mar S, et al
    Pediatric acquired CNS demyelinating syndromes: Features associated with multiple sclerosis.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  31. KRUPP LB, Rintell D, Charvet LE, Milazzo M, et al
    Pediatric multiple sclerosis: Perspectives from adolescents and their families.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  32. CHITNIS T, Ghezzi A, Bajer-Kornek B, Boyko A, et al
    Pediatric multiple sclerosis: Escalation and emerging treatments.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  33. BANWELL B
    Pediatric multiple sclerosis: The 2015 Sydney Carter Award Lecture.
    Neurology. 2016;87:822-6.
    PubMed     Text format    


  34. KHALIL M, Salzer J
    CSF neurofilament light: A universal risk biomarker in multiple sclerosis?
    Neurology. 2016 Aug 12. pii: 10.1212/WNL.0000000000003107.
    PubMed     Text format    



  35. Journal Club: Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2016;87:646.
    PubMed     Text format    


  36. JONES DE, Sutliff MH, Halper J, Armstrong MJ, et al
    Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2016;87:646.
    PubMed     Text format    


    July 2016
  37. PURCHIARONI F, Salvetti M, Buscarinu MC, Annibale B, et al
    Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003045.
    PubMed     Text format    


  38. BENOIT A, Durand-Dubief F, Amato MP, Portaccio E, et al
    History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003036.
    PubMed     Text format     Abstract available


  39. GILMORE W, Airas L
    Successive pregnancies in multiple sclerosis.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003039.
    PubMed     Text format    


  40. GOLAN D, Miller A, Sotirchos ES, Bhargava P, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:446.
    PubMed     Text format    


  41. AVASARALA J, Sotirchos ES, Bhargava P, Calabresi PA, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:445-6.
    PubMed     Text format    


  42. PREZIOSA P, Comi G, Filippi M
    Optic neuritis in multiple sclerosis: Looking from a patient's eyes.
    Neurology. 2016;87:338-9.
    PubMed     Text format    


  43. MILLER AE, Pelletier D
    Multiple sclerosis: Rapid diagnosis or right diagnosis?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002994.
    PubMed     Text format    


    June 2016
  44. WANG G, Marrie RA, Salter AR, Fox R, et al
    Health insurance affects the use of disease-modifying therapy in multiple sclerosis.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002887.
    PubMed     Text format     Abstract available


  45. LEHMANN-HORN K, Penkert H, Grein P, Leppmeier U, et al
    PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Neurology. 2016 Jun 24. pii: 10.1212/WNL.0000000000002900.
    PubMed     Text format    


  46. DE FLON P, Gunnarsson M, Laurell K, Soderstrom L, et al
    Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
    Neurology. 2016 Jun 17. pii: 10.1212/WNL.0000000000002832.
    PubMed     Text format     Abstract available


    May 2016
  47. KARAMYAN A, Sellner J
    Journal Club: Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2016;86:e228-30.
    PubMed     Text format    


  48. SENA A, Capela C, Ferret-Sena V, Munger KL, et al
    No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
    Neurology. 2016;86:2026.
    PubMed     Text format    


  49. BUTTMANN M, Seuffert L, Mader U, Toyka KV, et al
    Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.
    Neurology. 2016 May 11. pii: 10.1212/WNL.0000000000002745.
    PubMed     Text format     Abstract available


  50. TRUINI A, Prosperini L, Calistri V, Fiorelli M, et al
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016 May 4. pii: 10.1212/WNL.0000000000002720.
    PubMed     Text format     Abstract available


    April 2016
  51. SUMOWSKI JF, Rocca MA, Leavitt VM, Meani A, et al
    Brain reserve against physical disability progression over 5 years in multiple sclerosis.
    Neurology. 2016 Apr 27. pii: 10.1212/WNL.0000000000002702.
    PubMed     Text format     Abstract available



  52. Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2016;86:1465.
    PubMed     Text format    


  53. MCDONNELL GV, Bennett A, Rae-Grant A, Bever C, et al
    Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2016;86:1361.
    PubMed     Text format    


  54. BENNETT A, Rae-Grant A, Bever C
    Author Response.
    Neurology. 2016;86:1361.
    PubMed     Text format    


    March 2016
  55. GRANT WB, Riise T
    Multiple sclerosis: A lifestyle disease?
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002487.
    PubMed     Text format    


  56. BERRIGAN LI, Fisk JD, Patten SB, Tremlett H, et al
    Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002564.
    PubMed     Text format     Abstract available


  57. MARRIE RA, Patten SB, Tremlett H, Wolfson C, et al
    Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002481.
    PubMed     Text format     Abstract available


  58. O'CONNOR P, Comi G, Freedman MS, Miller AE, et al
    Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
    Neurology. 2016;86:920-30.
    PubMed     Text format     Abstract available


  59. ZHANG T, Tremlett H, Leung S, Zhu F, et al
    Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
    Neurology. 2016 Mar 4. pii: 10.1212/WNL.0000000000002543.
    PubMed     Text format     Abstract available


    February 2016
  60. BARBIN L, Rousseau C, Jousset N, Casey R, et al
    Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Neurology. 2016;86:771-8.
    PubMed     Text format     Abstract available


  61. MARRIE RA, Miller A, Sormani MP, Thompson A, et al
    The challenge of comorbidity in clinical trials for multiple sclerosis.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002471.
    PubMed     Text format     Abstract available


  62. DILOKTHORNSAKUL P, Valuck RJ, Nair KV, Corboy JR, et al
    Multiple sclerosis prevalence in the United States commercially insured population.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002469.
    PubMed     Text format     Abstract available


  63. MARRIE RA, Miller A, Sormani MP, Thompson A, et al
    Recommendations for observational studies of comorbidity in multiple sclerosis.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002474.
    PubMed     Text format     Abstract available


  64. CORTESE I, Ohayon J, Fenton K, Lee CC, et al
    Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
    Neurology. 2016 Feb 3. pii: 10.1212/WNL.0000000000002417.
    PubMed     Text format     Abstract available


  65. HAN C, Huang J, Waxman SG
    Sodium channel Nav1.8: Emerging links to human disease.
    Neurology. 2016;86:473-83.
    PubMed     Text format     Abstract available


    January 2016
  66. SHEIKH Z, Jain S, Hillen M
    Acute retinal necrosis in multiple sclerosis: A neuroimmunologic challenge!
    Neurology. 2016 Jan 29. pii: 10.1212/WNL.0000000000002450.
    PubMed     Text format    


  67. BOURRE B, Gueudry J, Lefaucheur R, Borden A, et al
    Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
    Neurology. 2016;86:312-3.
    PubMed     Text format    


  68. LINCOLN MR, Schneider R, Hohol M
    Clinical Reasoning: A 34-year-old man with headache, diplopia, and hemiparesis.
    Neurology. 2016;86:e24-8.
    PubMed     Text format    


  69. CHITNIS T, Ness J, Krupp L, Waubant E, et al
    Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.
    Neurology. 2016;86:245-52.
    PubMed     Text format     Abstract available


  70. BODINI B, Chard D, Altmann DR, Tozer D, et al
    White and gray matter damage in primary progressive MS: The chicken or the egg?
    Neurology. 2016;86:170-6.
    PubMed     Text format     Abstract available


  71. WAXMAN SG, Kantarci O
    The cerebellar channelopathy of multiple sclerosis.
    Neurology. 2016 Jan 6. pii: 10.1212/WNL.0000000000002338.
    PubMed     Text format    


  72. ROOSTAEI T, Sadaghiani S, Park MT, Mashhadi R, et al
    Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
    Neurology. 2016 Jan 6. pii: 10.1212/WNL.0000000000002326.
    PubMed     Text format     Abstract available


    December 2015
  73. SOTIRCHOS ES, Bhargava P, Eckstein C, Van Haren K, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002316.
    PubMed     Text format     Abstract available


  74. LIEBERMAN LA, Zeng W, Singh C, Wang W, et al
    CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002314.
    PubMed     Text format     Abstract available


  75. MARRIE RA, Fisk JD, Tremlett H, Wolfson C, et al
    Differences in the burden of psychiatric comorbidity in MS vs the general population.
    Neurology. 2015;85:1972-9.
    PubMed     Text format     Abstract available


    November 2015
  76. HASELKORN JK, Hughes C, Rae-Grant A, Henson LJ, et al
    Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2015;85:1896-903.
    PubMed     Text format     Abstract available



  77. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Neurology. 2015;85:1728.
    PubMed     Text format    


  78. TISCHNER JR, Hartung DM, Bourdette DN, Whitham RH, et al
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  79. RITTENHOUSE BE
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  80. HARTUNG DM, Bourdette DN, Ahmed S, Whitham RH, et al
    Author response.
    Neurology. 2015;85:1728.
    PubMed     Text format    


  81. RITTENHOUSE BE
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  82. HARTUNG DM, Bourdette DN, Whitham RH
    Author response.
    Neurology. 2015;85:1727.
    PubMed     Text format    


  83. DE STEFANO N, Stromillo ML, Giorgio A, Battaglini M, et al
    Long-term assessment of no evidence of disease activity in relapsing-remitting MS.
    Neurology. 2015;85:1722-3.
    PubMed     Text format    


  84. DEBS R, Maillart E, Fahed R, Papeix C, et al
    Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies.
    Neurology. 2015;85:1630-2.
    PubMed     Text format    


    October 2015
  85. LOUAPRE C, Govindarajan ST, Gianni C, Langkammer C, et al
    Beyond focal cortical lesions in MS: An in vivo quantitative and spatial imaging study at 7T.
    Neurology. 2015 Oct 14. pii: 10.1212/WNL.0000000000002106.
    PubMed     Text format     Abstract available



  86. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
    Neurology. 2015;85:1355.
    PubMed     Text format    


  87. MUNGER KL, Fitzgerald KC, Freedman MS, Hartung HP, et al
    No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
    Neurology. 2015 Oct 9. pii: 10.1212/WNL.0000000000002099.
    PubMed     Text format     Abstract available


  88. LAURSEN JH, Sondergaard HB, Sorensen PS, Sellebjerg F, et al
    Association between age at onset of multiple sclerosis and vitamin D level-related factors.
    Neurology. 2015 Oct 7. pii: 10.1212/WNL.0000000000002075.
    PubMed     Text format     Abstract available


  89. BOVE R, Malik MT, Diaz-Cruz C, Chua A, et al
    The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS.
    Neurology. 2015;85:1209-13.
    PubMed     Text format     Abstract available


  90. LUCAS RM, Banwell B
    Do prenatal sex hormones modulate MS risk?
    Neurology. 2015;85:1193-4.
    PubMed     Text format    


    September 2015
  91. LABINER DM
    William A. Sibley, MD (1925-2015).
    Neurology. 2015;85:1016.
    PubMed     Text format    



  92. Meningeal inflammation in multiple sclerosis: The key to the origin of cortical lesions?
    Neurology. 2015;85:1010.
    PubMed     Text format    


  93. RAE-GRANT A, Bennett A, Sanders AE, Phipps M, et al
    Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2015 Sep 2. pii: 10.1212/WNL.0000000000001965.
    PubMed     Text format    


    August 2015
  94. PARDINI M, Yaldizli O, Sethi V, Muhlert N, et al
    Motor network efficiency and disability in multiple sclerosis.
    Neurology. 2015 Aug 28. pii: 10.1212/WNL.0000000000001970.
    PubMed     Text format     Abstract available


  95. SORMANI MP, Evangelou N
    New imaging language skills required in MS.
    Neurology. 2015 Aug 28. pii: 10.1212/WNL.0000000000001978.
    PubMed     Text format    


  96. HUANG D
    Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.
    Neurology. 2015 Aug 19. pii: 10.1212/WNL.0000000000001929.
    PubMed     Text format    


  97. RINGELSTEIN M, Albrecht P, Kleffner I, Buhn B, et al
    Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography.
    Neurology. 2015;85:610-8.
    PubMed     Text format     Abstract available


  98. ROCCA MA, Filippi M, Deiva K
    Promoting physical activity to control multiple sclerosis from childhood.
    Neurology. 2015 Aug 12. pii: 10.1212/WNL.0000000000001941.
    PubMed     Text format    


  99. GROVER SA, Aubert-Broche B, Fetco D, Collins DL, et al
    Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis.
    Neurology. 2015 Aug 12. pii: 10.1212/WNL.0000000000001939.
    PubMed     Text format     Abstract available


    July 2015
  100. HACOHEN Y, Zuberi S, Vincent A, Crow YJ, et al
    Neuromyelitis optica in a child with Aicardi-Goutieres syndrome.
    Neurology. 2015;85:381-3.
    PubMed     Text format    


  101. NOVOTNA M, Paz Soldan MM, Abou Zeid N, Kale N, et al
    Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
    Neurology. 2015 Jul 24. pii: 10.1212/WNL.0000000000001856.
    PubMed     Text format     Abstract available


  102. WINGERCHUK DM, Banwell B, Bennett JL, Cabre P, et al
    International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
    Neurology. 2015;85:177-89.
    PubMed     Text format     Abstract available


  103. KISTER I, Paul F
    Pushing the boundaries of neuromyelitis optica: does antibody make the disease?
    Neurology. 2015;85:118-9.
    PubMed     Text format    


  104. KAPPOS L, Radue EW, Comi G, Montalban X, et al
    Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
    Neurology. 2015;85:29-39.
    PubMed     Text format     Abstract available


  105. TRANAH GJ, Santaniello A, Caillier SJ, D'Alfonso S, et al
    Mitochondrial DNA sequence variation in multiple sclerosis.
    Neurology. 2015 Jul 1. pii: 10.1212/WNL.0000000000001744.
    PubMed     Text format     Abstract available


    June 2015
  106. DAAMS M, Steenwijk MD, Wattjes MP, Geurts JJ, et al
    Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis.
    Neurology. 2015 Jun 26. pii: 10.1212/WNL.0000000000001756.
    PubMed     Text format     Abstract available


  107. ROVIRA A, Wiggermann V, Rauscher A
    Trajectories of subcortical iron accumulation in MS.
    Neurology. 2015;84:2388-9.
    PubMed     Text format    


  108. PFENDER N, Jelcic I, Linnebank M, Schwarz U, et al
    Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
    Neurology. 2015;84:2377-8.
    PubMed     Text format    


    May 2015
  109. MARRIE RA, Elliott L, Marriott J, Cossoy M, et al
    Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2015 May 27. pii: 10.1212/WNL.0000000000001718.
    PubMed     Text format     Abstract available


  110. BROWN MG
    Cost of disease-modifying therapies for multiple sclerosis.
    Neurology. 2015;84:e181-5.
    PubMed     Text format    


  111. GILBERT GJ
    A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.
    Neurology. 2015;84:2201.
    PubMed     Text format    


  112. VAN TASSEL SH, Gupta MP, Orlin A, Nealon NM, et al
    Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
    Neurology. 2015;84:2198-9.
    PubMed     Text format    


  113. MURRAY TJ, Brown MG
    Escalating MS drug costs in the US: Puzzling, troubling, and suspicious.
    Neurology. 2015;84:2105-6.
    PubMed     Text format    


  114. KHALIL M, Langkammer C, Pichler A, Pinter D, et al
    Dynamics of brain iron levels in multiple sclerosis: A longitudinal 3T MRI study.
    Neurology. 2015 May 15. pii: 10.1212/WNL.0000000000001679.
    PubMed     Text format     Abstract available


    April 2015
  115. WEINSHENKER BG, Barron G, Behne JM, Bennett JL, et al
    Challenges and opportunities in designing clinical trials for neuromyelitis optica.
    Neurology. 2015;84:1805-15.
    PubMed     Text format     Abstract available


  116. HARTUNG DM, Bourdette DN, Ahmed SM, Whitham RH, et al
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Neurology. 2015 Apr 24. pii: 10.1212/WNL.0000000000001608.
    PubMed     Text format     Abstract available


  117. MAINERO C, Louapre C
    Meningeal inflammation in multiple sclerosis: The key to the origin of cortical lesions?
    Neurology. 2015 Apr 17. pii: 10.1212/WNL.0000000000001586.
    PubMed     Text format    


  118. ABSINTA M, Vuolo L, Rao A, Nair G, et al
    Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
    Neurology. 2015 Apr 17. pii: 10.1212/WNL.0000000000001587.
    PubMed     Text format     Abstract available


  119. FRITZ NE, Newsome SD, Eloyan A, Marasigan RE, et al
    Longitudinal relationships among posturography and gait measures in multiple sclerosis.
    Neurology. 2015 Apr 15. pii: 10.1212/WNL.0000000000001580.
    PubMed     Text format     Abstract available


  120. FOX RJ
    A better measuring stick for walking in multiple sclerosis.
    Neurology. 2015 Apr 15. pii: 10.1212/WNL.0000000000001599.
    PubMed     Text format    


  121. TULLY T, Barkley A, Silber E
    Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod.
    Neurology. 2015 Apr 15. pii: 10.1212/WNL.0000000000001556.
    PubMed     Text format    


  122. LIU Y, Wang J, Daams M, Weiler F, et al
    Differential patterns of spinal cord and brain atrophy in NMO and MS.
    Neurology. 2015;84:1465-72.
    PubMed     Text format     Abstract available


    March 2015
  123. BIELEKOVA B, McDermott MP
    Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?
    Neurology. 2015 Mar 25. pii: 10.1212/WNL.0000000000001506.
    PubMed     Text format    


  124. KUHLE J, Disanto G, Lorscheider J, Stites T, et al
    Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
    Neurology. 2015 Mar 25. pii: 10.1212/WNL.0000000000001491.
    PubMed     Text format     Abstract available


  125. KAPPOS L, O'Connor P, Radue EW, Polman C, et al
    Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial.
    Neurology. 2015 Mar 20. pii: 10.1212/WNL.0000000000001462.
    PubMed     Text format     Abstract available


  126. MATTOSCIO M, Nicholas R, Sormani MP, Malik O, et al
    Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.
    Neurology. 2015 Mar 11. pii: 10.1212/WNL.0000000000001454.
    PubMed     Text format     Abstract available


  127. MURARO PA
    Andiamo! Moving forward with autologous hematopoietic transplantation for highly active MS.
    Neurology. 2015;84:968-9.
    PubMed     Text format    


  128. MECHELLI R, Manzari C, Policano C, Annese A, et al
    Epstein-Barr virus genetic variants are associated with multiple sclerosis.
    Neurology. 2015 Mar 4. pii: 10.1212/WNL.0000000000001420.
    PubMed     Text format     Abstract available


  129. JACQUES FH, Lublin FD
    Defining the clinical course of multiple sclerosis: The 2013 revisions.
    Neurology. 2015;84:963.
    PubMed     Text format    


  130. LUBLIN FD
    Author response.
    Neurology. 2015;84:963.
    PubMed     Text format    


    February 2015
  131. SEIBERT JB, Alvarez E
    Severe anemia in a patient with multiple sclerosis treated with natalizumab.
    Neurology. 2015;84:861.
    PubMed     Text format    


  132. KIM HJ, Paul F, Lana-Peixoto MA, Tenembaum S, et al
    MRI characteristics of neuromyelitis optica spectrum disorder: An international update.
    Neurology. 2015 Feb 18. pii: 10.1212/WNL.0000000000001367.
    PubMed     Text format     Abstract available


  133. MILLER DH, Fox RJ, Phillips JT, Hutchinson M, et al
    Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
    Neurology. 2015 Feb 13. pii: 10.1212/WNL.0000000000001360.
    PubMed     Text format     Abstract available


  134. MANCARDI GL, Sormani MP, Gualandi F, Saiz A, et al
    Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial.
    Neurology. 2015 Feb 11. pii: 10.1212/WNL.0000000000001329.
    PubMed     Text format     Abstract available


    January 2015
  135. GOLDMAN MD, Naismith RT
    Multiple sclerosis, immunomodulation, and immunizations: Balancing the benefits.
    Neurology. 2015 Jan 30. pii: 10.1212/WNL.0000000000001319.
    PubMed     Text format    


  136. KAPPOS L, Mehling M, Arroyo R, Izquierdo G, et al
    Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.
    Neurology. 2015 Jan 30. pii: 10.1212/WNL.0000000000001302.
    PubMed     Text format     Abstract available


  137. RADUE EW, Barkhof F, Kappos L, Sprenger T, et al
    Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.
    Neurology. 2015 Jan 28. pii: 10.1212/WNL.0000000000001281.
    PubMed     Text format     Abstract available


  138. CULPEPPER WJ 2ND, Wallin MT
    Comorbidity increases the risk of hospitalizations in MS: prevention opportunities.
    Neurology. 2015;84:335-6.
    PubMed     Text format    


  139. KEARNEY H, Altmann DR, Samson RS, Yiannakas MC, et al
    Cervical cord lesion load is associated with disability independently from atrophy in MS.
    Neurology. 2015;84:367-73.
    PubMed     Text format     Abstract available


  140. DEIVA K, Absoud M, Hemingway C, Hernandez Y, et al
    Acute idiopathic transverse myelitis in children: early predictors of relapse and disability.
    Neurology. 2015;84:341-9.
    PubMed     Text format     Abstract available


  141. SCHOONHEIM MM, Hulst HE, Brandt RB, Strik M, et al
    Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis.
    Neurology. 2015 Jan 23. pii: 10.1212/WNL.0000000000001285.
    PubMed     Text format     Abstract available


  142. CHARD DT, Benedict RH
    Paradoxes in thalamic function and cognition in people with multiple sclerosis: Less is more.
    Neurology. 2015 Jan 23. pii: 10.1212/WNL.0000000000001293.
    PubMed     Text format    


  143. BARKHOF F, Reich DS
    Can leptomeningeal enhancement be linked to multiple sclerosis?
    Neurology. 2015 Jan 23. pii: 10.1212/WNL.0000000000001292.
    PubMed     Text format    


  144. EISELE P, Griebe M, Szabo K, Wolf ME, et al
    Investigation of leptomeningeal enhancement in MS: A postcontrast FLAIR MRI study.
    Neurology. 2015 Jan 23. pii: 10.1212/WNL.0000000000001286.
    PubMed     Text format     Abstract available


  145. OH J, Sotirchos ES, Saidha S, Whetstone A, et al
    Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis.
    Neurology. 2015 Jan 21. pii: 10.1212/WNL.0000000000001257.
    PubMed     Text format     Abstract available


  146. POPESCU BF, Guo Y, Jentoft ME, Parisi JE, et al
    Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions.
    Neurology. 2015;84:148-58.
    PubMed     Text format     Abstract available


  147. FUJIHARA K, Misu T
    AQP4 in biopsied demyelinating lesions as a diagnostic clue to NMOSD and MS: final answer?
    Neurology. 2015;84:110-1.
    PubMed     Text format    


  148. ISSA NP, Hentati A
    VZV encephalitis that developed in an immunized patient during fingolimod therapy.
    Neurology. 2015;84:99-100.
    PubMed     Text format    


    December 2014
  149. MARRIE RA, Elliott L, Marriott J, Cossoy M, et al
    Comorbidity increases the risk of hospitalizations in multiple sclerosis.
    Neurology. 2014 Dec 24. pii: 10.1212/WNL.0000000000001187.
    PubMed     Text format     Abstract available


  150. HEMMER B, Calabresi PA
    Complex antibody profiling to predict clinical outcome in childhood ADS.
    Neurology. 2014;83:2200-1.
    PubMed     Text format    


  151. FREEMAN WD, Marrie RA, Garland A
    Intensive care unit admission in multiple sclerosis: Increased incidence and increased mortality.
    Neurology. 2014;83:2192-3.
    PubMed     Text format    


  152. CHITNIS T, Gorman MP
    Impact of MS during the critical window of brain development.
    Neurology. 2014;83:2106-7.
    PubMed     Text format    


  153. WARNKE C, Dehmel T, Ramanujam R, Holmen C, et al
    Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.
    Neurology. 2014;83:2153-7.
    PubMed     Text format     Abstract available


    November 2014
  154. FOX RJ
    Author response.
    Neurology. 2014;83:2100.
    PubMed     Text format    


  155. SVENNINGSSON A, Sundstrom P, Salzer J, Vagberg M, et al
    MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.
    Neurology. 2014;83:2099-100.
    PubMed     Text format    


  156. GRAVES J, Grandhe S, Weinfurtner K, Krupp L, et al
    Protective environmental factors for neuromyelitis optica.
    Neurology. 2014;83:1923-9.
    PubMed     Text format     Abstract available


  157. PAZ SOLDAN MM, Novotna M, Abou Zeid N, Kale N, et al
    Relapses and disability accumulation in progressive multiple sclerosis.
    Neurology. 2014 Nov 14. pii: 10.1212/WNL.0000000000001094.
    PubMed     Text format     Abstract available


  158. EHLING R, Lutterotti A, Brenneis C, Zee DS, et al
    Damping of monocular pendular nystagmus with vibration in a patient with multiple sclerosis.
    Neurology. 2014;83:1879.
    PubMed     Text format    


  159. ZEE DS, Beh SC, Kheradmand A
    Author response.
    Neurology. 2014;83:1879.
    PubMed     Text format    


  160. NAISMITH RT, Cross AH
    Antisense therapy: potential tool to reduce activity in MS via protein expression inhibition.
    Neurology. 2014;83:1776-7.
    PubMed     Text format    


  161. LIMMROTH V, Barkhof F, Desem N, Diamond MP, et al
    CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.
    Neurology. 2014;83:1780-8.
    PubMed     Text format     Abstract available


  162. QUINTANA FJ, Patel B, Yeste A, Nyirenda M, et al
    Epitope spreading as an early pathogenic event in pediatric multiple sclerosis.
    Neurology. 2014 Nov 7. pii: 10.1212/WNL.0000000000001066.
    PubMed     Text format     Abstract available


  163. AUBERT-BROCHE B, Fonov V, Narayanan S, Arnold DL, et al
    Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
    Neurology. 2014 Nov 5. pii: 10.1212/WNL.0000000000001045.
    PubMed     Text format     Abstract available


  164. TUR C, Ramagopalan S, Altmann DR, Bodini B, et al
    HLA-DRB1*15 influences the development of brain tissue damage in early PPMS.
    Neurology. 2014;83:1712-8.
    PubMed     Text format     Abstract available


    October 2014
  165. NAISMITH RT, Narayanan D
    Examining multiple sclerosis through the eyes of a child.
    Neurology. 2014 Oct 31. pii: 10.1212/WNL.0000000000001060.
    PubMed     Text format    


  166. HUBER AK, Wang L, Han P, Zhang X, et al
    Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS.
    Neurology. 2014;83:1500-7.
    PubMed     Text format     Abstract available


  167. ASGARI N, Henriksen TB, Petersen T, Lillevang ST, et al
    Pregnancy outcomes in a woman with neuromyelitis optica.
    Neurology. 2014;83:1576-7.
    PubMed     Text format    


  168. YEO LL, Wieder N, Wang AS, Ting E, et al
    Pearls & Oy-sters: A cause of intractable vomiting.
    Neurology. 2014;83:e141-4.
    PubMed     Text format    


  169. TOOSY AT, Kou N, Altmann D, Wheeler-Kingshott CA, et al
    Voxel-based cervical spinal cord mapping of diffusion abnormalities in MS-related myelitis.
    Neurology. 2014;83:1321-5.
    PubMed     Text format     Abstract available


    September 2014
  170. SATO DK, Callegaro D, Lana-Peixoto MA, Horizonte B, et al
    Author response.
    Neurology. 2014;83:1122-3.
    PubMed     Text format    


  171. MAO Z, Lu Z, Hu X
    Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
    Neurology. 2014;83:1122.
    PubMed     Text format    


    July 2014
  172. AGNIHOTRI SP, Dang X, Carter JL, Fife TD, et al
    JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.
    Neurology. 2014 Jul 18. pii: 10.1212/WNL.0000000000000713.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: